CLINICAL_TRIALS
trial_result
· 2020-06-16
Clinical Trial Update: Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease [Phase 3]
Summary
Phase 3 trial update for LCI699 in Cushing's disease reports completed results on safety and efficacy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cushings Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-06-16